Market Research Logo

Orphan Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

Orphan Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024
The report on global orphan drugs market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global orphan drugs market to grow with a CAGR of 6.5% over the forecast period of 2018-2024. The study on orphan drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024.
These drugs are used to treat the population suffering from the very serious, but rare diseases for which no treatment available. There are around 25 to 30 million people are affected by this diseases in Europe. The awareness about the orphan drug is growing rapidly across the world that further leads to the growing adoption of orphan drug act in the japan, Australia, Europe and others countries to stimulate research and development in the orphan drug.
The orphan drug market segmented as diseases indication, product type, and distribution channels. The segment dieses type is further divided into sub segment including Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic disorders, Endocrinology, Infectious diseases and other. The product type segment included Biological and Non-bio logical products and distributed over the channels like hospital pharmacy, retail pharmacy and others.
Economic incentives to encourage drug companies to develop and market medicines for rare disease treatment is the key driving factor in the orphan drug market. The rising occurrence of rare cancer cases, availability of orphan drugs at hospital pharmacy and increasing hospitalization treatment for rare diseases are expected to enhance the growth of orphan drug market over the forecast period. On the other hand, the cost associate with production and R&D is more as compare with other drugs that may hampering the market growth. Moreover, the rising awareness of rare disease among population and increasing investments in R&D is projected to create several opportunities in upcoming years.
North America dominates the market of orphan drugs owing to its highly developed healthcare infrastructure and favorable government regulations. In North America U.S. holds largest market share in this market due to economic incentives and rising awareness about orphan drug.Moreover, the increasing investments to treat and diagnose the rare disease also to facilitate the growth in the orphan drug market.
The report on orphan drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global orphan drugs market over the period of 2016 to 2024. Moreover, the report is collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global orphan drugs market over the period of 2016 to 2024. Further, IGR- Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.

Research Methodology
A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through
1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers
Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.
The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global orphan drugs market is segmented on the basis of disease type, product types and distribution channel.

Global Orphan Drugs Market by Disease Type
Oncology
Gastrointestinal
Pulmonary
Hematology
Neurology
Infectious Diseases
Others
Global Orphan Drugs Market by Product Types
Biologic
Non-biologic
Global Orphan Drugs Market by Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies

Company Profiles
Novartis AG
Pfizer Inc.
Alexion Pharmaceuticals
Eisai Co. Ltd.
Bayer AG
Biogen Inc
Eli Lilly and Company
AstraZeneca plc.
GlaxoSmithKline
Johnson & Johnson

How this report delivers?
1. Comprehensive analysis of global as well as regional markets of orphan drugs market.
2. Complete coverage of all the segments in orphan drugs market to analyze the trends, developments in the global market and forecast of market size up to 2024.
3. Comprehensive analysis of the companies operating in global orphan drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.


The report on orphan drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global orphan drugs market over the period of 2016 to 2024. Moreover, the report is collective presentation of primary and secondary research findings.

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Orphan drugs market Highlights
2.2. Orphan drugs market Projection
2.3. Orphan drugs market Regional Highlights
3. Global Orphan Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. Porter's Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.4.1. IGR-Growth Matrix Analysis by Disease Type
3.4.2. IGR-Growth Matrix Analysis by Product Types
3.4.3. IGR-Growth Matrix Analysis by Distribution Channel
3.4.4. IGR-Growth Matrix Analysis by Region
3.5. Value chain Orphan drugs market
4. Orphan drugs market macro indicator analysis
5. Global Orphan Drugs Market by Disease Type
5.1. Oncology
5.2. Gastrointestinal
5.3. Pulmonary
5.4. Hematology
5.5. Neurology
5.6.Infectious Diseases
5.7. Others
6. Global Orphan Drugs Market by Product Types
6.1. Biologic
6.2. Non-biologic
7. Global Orphan Drugs Market by Distribution Channel
7.1. Hospital Pharmacies
7.2. Specialty Pharmacies
7.3. Retail Pharmacies
8. Global Orphan Drugs Market by Region 2018-2024
8.1. North America
8.1.1. North America Orphan Drugs Market by Disease Type
8.1.2. North America Orphan Drugs Market by Product Types
8.1.3. North America Orphan Drugs Market by Distribution Channel
8.1.4. North America Orphan Drugs Market by Country
8.2. Europe
8.2.1. Europe Orphan Drugs Market by Disease Type
8.2.2. Europe Orphan Drugs Market by Product Types
8.2.3. Europe Orphan Drugs Market by Distribution Channel
8.2.4. Europe Orphan Drugs Market by Country
8.3. Asia-Pacific
8.3.1. Asia-Pacific Orphan Drugs Market by Disease Type
8.3.2. Asia-Pacific Orphan Drugs Market by Product Types
8.3.3. Asia-Pacific Orphan Drugs Market by Distribution Channel
8.3.4. Asia-Pacific Orphan Drugs Market by Country
8.4. RoW
8.4.1. RoW Orphan Drugs Market by Disease Type
8.4.2. RoW Orphan Drugs Market by Product Types
8.4.3. RoW Orphan Drugs Market by Distribution Channel
8.4.4. RoW Orphan Drugs Market by Sub-region
9. Company profiles and competitive landscape
9.1. Competitive Landscape in the Global Orphan Drugs Market
9.2. Companies Profiles
9.2.1. Novartis Ag
9.2.1.1. Overview
9.2.1.2. Company Snapshot
9.2.1.3. Financial Snapshot
9.2.1.4. Product portfolio
9.2.1.5. Recent developments
9.2.2. Pfizer Inc.
9.2.2.1. Overview
9.2.2.2. Company Snapshot
9.2.2.3. Financial Snapshot
9.2.2.4. Product portfolio
9.2.2.5. Recent developments
9.2.3. Alexion Pharmaceuticals
9.2.3.1. Overview
9.2.3.2. Company Snapshot
9.2.3.3. Financial Snapshot
9.2.3.4. Product portfolio
9.2.3.5. Recent developments
9.2.4. Eisai Co. Ltd.
9.2.4.1. Overview
9.2.4.2. Company Snapshot
9.2.4.3. Financial Snapshot
9.2.4.4. Product portfolio
9.2.4.5. Recent developments
9.2.5. Bayer Ag
9.2.5.1. Overview
9.2.5.2. Company Snapshot
9.2.5.3. Financial Snapshot
9.2.5.4. Product portfolio
9.2.5.5. Recent developments
9.2.6. Biogen Inc
9.2.6.1. Overview
9.2.6.2. Company Snapshot
9.2.6.3. Financial Snapshot
9.2.6.4. Product portfolio
9.2.6.5. Recent developments
9.2.7. Eli Lilly And Company
9.2.7.1. Overview
9.2.7.2. Company Snapshot
9.2.7.3. Financial Snapshot
9.2.7.4. Product portfolio
9.2.7.5. Recent developments
9.2.8. Astrazeneca Plc.
9.2.8.1. Overview
9.2.8.2. Company Snapshot
9.2.8.3. Financial Snapshot
9.2.8.4. Product portfolio
9.2.8.5. Recent developments
9.2.9. Glaxosmithkline
9.2.9.1. Overview
9.2.9.2. Company Snapshot
9.2.9.3. Financial Snapshot
9.2.9.4. Product portfolio
9.2.9.5. Recent developments
9.2.10. Johnson & Johnson
9.2.10.1. Overview
9.2.10.2. Company Snapshot
9.2.10.3. Financial Snapshot
9.2.10.4. Product portfolio
9.2.10.5. Recent developments
10. Appendix
10.1. Primary research findings and questionnaire

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report